Compound Evidence File
#EC-2026-0903
NAD+ Injectable
Filed under Injectable Oils. The bureau holds 142 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Apr 2026 | 5 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 16 Mar 2026 | 6 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Jan 2026 | 5 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Mar 2026 | 10 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 10 May 2026 | 8 Aug 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 10.0 | 10.0 | 21 Feb 2026 | 12 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 26 Jan 2026 | 28 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 10.0 | 10.0 | 1 May 2026 | 5 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jan 2026 | 6 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 10.0 | 10.0 | 5 Feb 2026 | 27 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Jun 2026 | 23 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Dec 2025 | 13 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 25 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 2 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 10 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Jan 2026 | 28 Mar 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 26 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 5 May 2026 | 17 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 4 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 28 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 25 Apr 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.6 | 9.1 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 9.0 | 7.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 8.9 | 8.9 | 8.9 | 14 Jan 2025 | 14 Jan 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.5 | 7.5 | 9.8 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.0 | 6.3 | 9.2 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 7.8 | 6.7 | 8.8 | 21 May 2026 | 21 May 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 7.7 | 7.7 | 7.7 | 2 Jul 2025 | 2 Jul 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 11 | 7.1 | 5.3 | 9.9 | 16 Mar 2025 | 20 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 7 | 7.1 | 4.6 | 8.5 | 20 Jun 2025 | 24 May 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 4 | 6.9 | 5.4 | 8.1 | 8 Jul 2025 | 23 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 4 | 6.4 | 4.6 | 8.2 | 27 Feb 2025 | 17 May 2026 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 6.4 | 6.4 | 6.4 | 8 Jul 2025 | 8 Jul 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 6.3 | 6.3 | 6.3 | 27 Feb 2025 | 27 Feb 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 6.2 | 6.2 | 6.2 | 27 Feb 2025 | 27 Feb 2025 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 6.1 | 4.0 | 8.3 | 21 May 2025 | 24 May 2026 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 6.1 | 6.1 | 6.1 | 25 Apr 2025 | 25 Apr 2025 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 6.0 | 6.0 | 6.0 | 8 Jul 2025 | 8 Jul 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 4.2 | 4.2 | 4.2 | 3 Jul 2025 | 3 Jul 2025 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 3.7 | 3.7 | 3.7 | 9 Jun 2025 | 9 Jun 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 1 | 2.5 | 2.5 | 2.5 | 8 Jul 2025 | 8 Jul 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 1.7 | 1.7 | 1.7 | 16 Mar 2025 | 16 Mar 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 | 24 Apr 2025 |
Open any subject to view the batch-level evidence for NAD+ Injectable alone.